These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Immunisation of mares with binding domains of toxins A and B of Clostridium difficile elicits serum and colostral antibodies that block toxin binding. Artiushin S; Timoney JF; Fettinger M; Fallon L; Rathgeber R Equine Vet J; 2013 Jul; 45(4):476-80. PubMed ID: 23206274 [TBL] [Abstract][Full Text] [Related]
23. The structure of Clostridium difficile toxin A glucosyltransferase domain bound to Mn2+ and UDP provides insights into glucosyltransferase activity and product release. D'Urzo N; Malito E; Biancucci M; Bottomley MJ; Maione D; Scarselli M; Martinelli M FEBS J; 2012 Sep; 279(17):3085-97. PubMed ID: 22747490 [TBL] [Abstract][Full Text] [Related]
24. The recombinant Lactococcus lactis oral vaccine induces protection against C. difficile spore challenge in a mouse model. Guo S; Yan W; McDonough SP; Lin N; Wu KJ; He H; Xiang H; Yang M; Moreira MA; Chang YF Vaccine; 2015 Mar; 33(13):1586-95. PubMed ID: 25698490 [TBL] [Abstract][Full Text] [Related]
25. Molecular methods to study transcriptional regulation of Clostridium difficile toxin genes. Antunes A; Dupuy B Methods Mol Biol; 2010; 646():93-115. PubMed ID: 20597005 [TBL] [Abstract][Full Text] [Related]
26. Carbohydrate recognition by Clostridium difficile toxin A. Greco A; Ho JG; Lin SJ; Palcic MM; Rupnik M; Ng KK Nat Struct Mol Biol; 2006 May; 13(5):460-1. PubMed ID: 16622409 [TBL] [Abstract][Full Text] [Related]
27. Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence Gal alpha 1-3Gal beta 1-4GlcNAc. Krivan HC; Clark GF; Smith DF; Wilkins TD Infect Immun; 1986 Sep; 53(3):573-81. PubMed ID: 3744552 [TBL] [Abstract][Full Text] [Related]
28. A Panel of Recombinant Mucins Carrying a Repertoire of Sialylated O-Glycans Based on Different Core Chains for Studies of Glycan Binding Proteins. Cherian RM; Jin C; Liu J; Karlsson NG; Holgersson J Biomolecules; 2015 Aug; 5(3):1810-31. PubMed ID: 26274979 [TBL] [Abstract][Full Text] [Related]
30. Evidence for dual receptor-binding sites in Clostridium difficile toxin A. Lambert GS; Baldwin MR FEBS Lett; 2016 Dec; 590(24):4550-4563. PubMed ID: 27861794 [TBL] [Abstract][Full Text] [Related]
31. Effective Sequestration of Clostridium difficile Protein Toxins by Calcium Aluminosilicate. Sturino JM; Pokusaeva K; Carpenter R Antimicrob Agents Chemother; 2015 Dec; 59(12):7178-83. PubMed ID: 26149988 [TBL] [Abstract][Full Text] [Related]
32. Substrate specificity of clostridial glucosylating toxins and their function on colonocytes analyzed by proteomics techniques. Zeiser J; Gerhard R; Just I; Pich A J Proteome Res; 2013 Apr; 12(4):1604-18. PubMed ID: 23387933 [TBL] [Abstract][Full Text] [Related]
33. O-glycan repertoires on a mucin-type reporter protein expressed in CHO cell pools transiently transfected with O-glycan core enzyme cDNAs. Liu J; Jin C; Cherian RM; Karlsson NG; Holgersson J J Biotechnol; 2015 Apr; 199():77-89. PubMed ID: 25722186 [TBL] [Abstract][Full Text] [Related]
34. A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models. Tian JH; Fuhrmann SR; Kluepfel-Stahl S; Carman RJ; Ellingsworth L; Flyer DC Vaccine; 2012 Jun; 30(28):4249-58. PubMed ID: 22537987 [TBL] [Abstract][Full Text] [Related]
35. Surface proteins from Lactobacillus kefir antagonize in vitro cytotoxic effect of Clostridium difficile toxins. Carasi P; Trejo FM; Pérez PF; De Antoni GL; Serradell Mde L Anaerobe; 2012 Feb; 18(1):135-42. PubMed ID: 22126976 [TBL] [Abstract][Full Text] [Related]
36. Clostridium difficile toxins: more than mere inhibitors of Rho proteins. Genth H; Dreger SC; Huelsenbeck J; Just I Int J Biochem Cell Biol; 2008; 40(4):592-7. PubMed ID: 18289919 [TBL] [Abstract][Full Text] [Related]
37. Purification and characterisation of intracellular toxin A of Clostridium difficile. Meng XQ; Kamiya S; Yamakawa K; Ogura H; Nakamura S J Med Microbiol; 1993 Jan; 38(1):69-73. PubMed ID: 8418298 [TBL] [Abstract][Full Text] [Related]
38. Comparison of wild type with recombinant Clostridium difficile toxin A. Gerhard R; Burger S; Tatge H; Genth H; Just I; Hofmann F Microb Pathog; 2005; 38(2-3):77-83. PubMed ID: 15748809 [TBL] [Abstract][Full Text] [Related]
39. Comparison of VIDAS CDAB and CDA immunoassay for the detection of Clostridium difficile in a tcdA- tcdB+ C. difficile prevalent area. Shin BM; Lee EJ; Kuak EY; Yoo SJ Anaerobe; 2009 Dec; 15(6):266-9. PubMed ID: 19772927 [TBL] [Abstract][Full Text] [Related]
40. Preparation and preliminary application of monoclonal antibodies to the receptor binding region of Clostridium difficile toxin B. Chen W; Liu WE; Li YM; Luo S; Zhong YM Mol Med Rep; 2015 Nov; 12(5):7712-20. PubMed ID: 26459027 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]